1. Home
  2. CYTK vs MBLY Comparison

CYTK vs MBLY Comparison

Compare CYTK & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$68.45

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Logo Mobileye Global Inc.

MBLY

Mobileye Global Inc.

HOLD

Current Price

$11.76

Market Cap

9.3B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
MBLY
Founded
1997
1999
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
9.3B
IPO Year
2004
2022

Fundamental Metrics

Financial Performance
Metric
CYTK
MBLY
Price
$68.45
$11.76
Analyst Decision
Strong Buy
Buy
Analyst Count
15
18
Target Price
$77.87
$19.29
AVG Volume (30 Days)
1.9M
4.1M
Earning Date
11-05-2025
10-23-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$87,211,000.00
$1,938,000,000.00
Revenue This Year
$363.61
$15.48
Revenue Next Year
$64.33
$7.59
P/E Ratio
N/A
N/A
Revenue Growth
2609.26
7.61
52 Week Low
$29.31
$10.74
52 Week High
$69.33
$22.51

Technical Indicators

Market Signals
Indicator
CYTK
MBLY
Relative Strength Index (RSI) 62.93 42.15
Support Level $59.85 $10.93
Resistance Level $67.98 $12.54
Average True Range (ATR) 2.72 0.44
MACD 0.13 0.02
Stochastic Oscillator 91.35 45.34

Price Performance

Historical Comparison
CYTK
MBLY

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About MBLY Mobileye Global Inc.

Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Others. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.

Share on Social Networks: